Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04594798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 31, 2026 → Jul 31, 2027
See other at-risk trials from University of Rochester

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Jul 31, 2027
    • Eligibility criteria expanded, about 36 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  3. Primary and study completion dates: Jul 31, 2024 to Jul 31, 2026v8
  4. 3 versions Re-verified since Jan 6, 2022, no change to tracked fieldsv5-v7
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Oct 31, 2021 to Sep 20, 2021
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jul 2, 2021 to Oct 31, 2021v3
  2. Start date: Jan 2, 2021 to Jul 2, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Trial Details
NCT Number NCT04594798
Lead Sponsor University of Rochester
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 DLBCL, Lymphoma, B-Cell
Related terms Lymphoma, B-Cell
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov